| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Fundamentals of Clinical Research for Radiologists |
1 Department of Radiology, University of Pennsylvania Medical Center, Medical
Center, Philadelphia, PA 19104.
2 Departments of Biostatistics and Epidemiology and Radiology, The Cleveland
Clinic Foundation, Cleveland, OH 44195.
Series editors: Nancy Obuchowski, C. Craig Blackmore, Steven Karlik, and
Caroline Reinhold.
Defining Diagnostic Test Accuracy
Sensitivity and Specificity
There are two basic measures of the inherent accuracy of a diagnostic test:
sensitivity and specificity. They are equally important, and one should never
be reported without the other. Sensitivity is the probability of a positive
test result (that is, the test indicates the presence of disease) for a
patient with the disease. Specificity, on the other hand, is the probability
of a negative test result (that is, the test does not indicate the presence of
disease) for a patient without the disease. We use the term
"disease" here loosely to mean the condition (e.g., breast cancer,
deep venous thrombosis, intracranial aneurysm) that the diagnostic test is
supposed to detect. We calculate the test's specificity based on patients
without this condition, but these patients often have other diseases.
Table 1 summarizes the definitions of sensitivity and specificity [1]. The table rows give the results of the diagnostic test, as either positive for the disease of interest or negative for the disease of interest. The columns indicate the true disease status, as either disease present or disease absent. True-positives (TPs) are those patients with the disease who test positive. True-negatives (TNs) are those without the disease who test negative. False-negatives (FNs) are those with the disease but the test falsely indicates the disease is not present. False-positives (FPs) are those without the disease but the test falsely indicates the presence of disease. Sensitivity, then, is the probability of a TP among patients with the disease (TPs + FNs). Specificity is the probability of a TN among patients without the disease (TNs + FPs).
|
Consider the following example. Carpenter et al. [2] evaluated the diagnostic accuracy of MR venography (MRV) to detect deep venous thrombosis (DVT). They performed MRV in a group of 85 patients who presented with clinical symptoms of DVT. The patients also underwent contrast venography, which is an invasive procedure considered to provide an unequivocal diagnosis for DVT (the so-called "gold standard test" or "standard of reference"). Of a total of 101 venous systems evaluated, 27 had DVT by contrast venography. All 27 cases were detected on MRV; thus, the sensitivity of MRV was 27/27, or 100%. Of 74 venous systems without DVT, as confirmed by contrast venography, three tested positive on MRV (that is, three FPs). The specificity of MRV was 71/74, or 96% specificity (Table 2).
|
Combining Multiple Tests
Few diagnostic tests are both highly sensitive and highly specific. For
this reason, patients sometimes are diagnosed using two or more tests. These
tests may be performed either in parallel (i.e., at the same time and
interpreted together) or in series (i.e., the results of the first test
determine whether the second test is performed at all)
[3]. The latter has the
advantage of avoiding unnecessary tests, but the disadvantage of potentially
delaying treatment for diseased patients by lengthening the diagnostic testing
period.
Tests can be interpreted in parallel in two ways. The first, called "the OR rule," yields a positive diagnosis if either test (let's assume there are two tests) is positive and a negative diagnosis if both tests are negative. That is, if test A and test B are both negative, then the combined result is negative, but if either or both are positive, then the combined result is positive.
The second rule, called "the AND rule," yields a positive diagnosis only if both tests are positive and a negative diagnosis if either test is negative. That is, if test A and test B are both positive, then the combined result is positive, but if either or both are negative, then the combined result is negative.
Let us denote the sensitivities of the two tests by SEa and SEb, and their specificities by SPa and SPb. To calculate the sensitivity of the combined test in parallel using the OR rule, the formula is: SEa + SEb - (SEa x SEb). Specificity under the OR rule is simply SPa x SPb. Conversely, to calculate sensitivity using the AND rule, the formula is: SEa x SEb, while specificity under the AND rule is SPa + SPb - (SPa x SPb).
Under the OR rule, the sensitivity of the combined result is higher than that of either test alone, but the combined specificity is lower than that of either test. With the AND rule, this is reversed: The specificity of the combined result is higher than either test alone, but the combined sensitivity is lower than that of either test.
Serial testing is an alternative to parallel testing that is particularly cost-efficient when screening for rare conditions and often is used when the second test is expensive and/or risky. Under the OR rule, if the first test is positive, the diagnosis is positive; otherwise, the second test is performed. If the second test is positive after a negative first test, then the diagnosis also is positive; otherwise, the diagnosis is negative. The OR rule, then, leads to a higher overall sensitivity than either test by itself. With the AND rule, if the first test is positive, the second test is performed. If the second test is positive, the diagnosis is positive; otherwise, the diagnosis is negative. The AND rule, then, leads to a higher overall specificity than either test by itself.
To calculate sensitivity of the combined test using serial testing with the OR rule, the formula is: SEa + (1 - SEa) x SEb. Specificity under the OR rule is simply SPa x SPb. Conversely, to calculate sensitivity using the AND rule, the formula is: SEa x SEb, while specificity under the AND rule is SPa + (1 - SPa) x SPb.
ROC Curves
While some tests provide dichotomous results (that is, positive or
negative), other tests yield results that are numeric values (for example,
attenuation of a lesion on CT) or ordered categories (for example, BI-RADS
scoring used in mammography). Consider CT attenuation as a diagnostic test for
distinguishing papillary renal cell carcinomas from other types of renal
masses [4]. In
Table 3, the ratio of tumor
enhancement to normal kidney enhancement (T–K ratio) of 10 masses is
listed.
|
How do we calculate the basic measures of accuracy, that is, sensitivity and specificity, for T–K ratio as a diagnostic test for papillary masses? We shall consider each unique T–K ratio value as a "cutoff," or "decision threshold" and calculate the sensitivity and specificity associated with each cutoff. Masses with T–K ratio values greater than or equal to the cutoff are called "negative" for papillary lesions and masses with T–K ratio values less than the cutoff are called "positive" for papillary lesions. In Table 3, the third and fourth columns give the calculated sensitivity and specificity, respectively, using the T–K ratio value in column 2 as the cutoff. Note that as the value of the cutoff increases, the specificity decreases while the sensitivity increases.
In Figure 1, we have plotted the 10 pairs of sensitivity and specificity calculated in Table 3. The y-axis is the sensitivity and the x-axis is 1 minus the specificity, or the false-positive rate (FPR). Connecting these points with line segments, we have constructed an ROC curve [5]. A test with an ROC curve that lies near the "chance diagonal line" in Figure 1 has no ability, beyond mere guessing, at distinguishing between patients with and without the disease. In contrast, a test with an ROC curve that passes near the upper left corner (that is, near 100% sensitivity and 0% FPR [100% specificity]) is nearly perfect at distinguishing disease from no disease. T–K ratio has moderate accuracy, with its ROC curve falling between these two extremes.
|
Suppose now that an investigator proposes the ratio of the attenuation of the mass to the attenuation of the abdominal aorta (T–A ratio) as a new diagnostic test for papillary lesions. This investigator, however, arbitrarily chooses a single cutoff and reports only the sensitivity and specificity at that cutoff. Figure 2 illustrates this single point (labeled A) in relation to the ROC curve for T–K ratio. We might be tempted to conclude that T–K ratio is superior to T–A ratio because point A falls below the ROC curve for T–K ratio. There are, however, an infinite number of ROC curves that could pass through point A, two of which are depicted by dashed curves in Figure 2. Some of these ROC curves could be superior to the ROC curve for T–K ratio for most FPRs and others inferior. Based on the single sensitivity and specificity reported by the investigator, we cannot determine if the T–A ratio is superior or inferior in relation to the T–K ratio. However, if we had been given the ROC curves of both the T–A and T–K ratio, then we could compare these two diagnostic tests and determine, for any range of FPRs, which test is preferred.
|
This example illustrates the importance of ROC curves and why they have become the state-of-the-art method for describing the diagnostic accuracy of a test. In a future module in this series Obuchowski [6] provides a detailed account of ROC curves, including constructing smooth ROC curves, estimating various summary measures of accuracy derived from them, finding the optimal cutoff on the ROC curve for a particular clinical application, and identifying available software.
Interpretation of Diagnostic Tests
Calculating the Positive and Negative Predictive Values
Clinicians are faced each day with the challenge of deciding appropriate
management for patients, based at least in part on the results of less than
perfect diagnostic tests. These clinicians need answers to the following
questions. "What is the likelihood that this patient has the disease
when the test result is positive?" and "What is the likelihood
that this patient does not have the disease when the test result is
negative?" The answers to these questions are known as the positive and
negative predictive values, respectively. We illustrate these with the
following example.
The lemon sign has been described as an important indicator of spina
bifida. Nyberg et al. [7]
describe the sensitivity and specificity of the lemon sign in the detection of
spina bifida in a high-risk population (elevated material serum
-fetoprotein level, suspected hydrocephalus or neural tube defect, or
family history of neural tube defect). A portion of their data is summarized
in Table 4.
|
Spina bifida occurred in 6.1% (14/229) of the sample, that is, sample prevalence was 6.1%. The lemon sign was seen in 92.9% (13/14) of the fetuses with spina bifida (92.9% sensitivity), and was absent in 98.6% (212/215) of the fetuses without spina bifida (98.6% specificity).
We also can calculate the positive and negative predictive values of the
lemon sign from the available data. The positive predictive value (PPV) is the
probability that the fetus has spina bifida when the lemon sign is present.
The PPV is calculated as follows:
 | (1) |
The corollary to the PPV is the negative predictive value (NPV), that is,
the probability that spina bifida will not be present when the lemon sign is
absent. The NPV is calculated as follows:
 | (2) |
The PPV and NPV can also be calculated from Bayes' theorem. Bayes' theorem allows us to compute the PPV and NPV from estimates of the test's sensitivity and specificity, and the probability of the disease before the test is applied. The latter is referred to as the pretest probability and is based on the patient's previous medical history, previous and recent exposures, current signs and symptoms, and results of other screening and diagnostic tests performed. When this information is unknown or when calculating the PPV or NPV for a population, the prevalence of the disease in the population is used as the pretest probability. The PPV and NPV, then, are called posttest probabilities (also, revised or posterior probabilities), and represent the probability of the disease after the test result is known.
Let p denote the pretest probability of disease, and SE and SP the
sensitivity and specificity of the diagnostic test. Recalling the expression
for a conditional probability (see module 10
[8]),
 | (3) |
 | (4) |
Thus, the posttest probability of disease for any patient can be calculated if one knows the accuracy of the test and the patient's pretest probability of disease.
The PPV and NPV can vary markedly, depending on the patient's pretest probability, or prevalence of disease in the population. In the Nyberg et al. [7] study the prevalence rate of spina bifida in their high risk sample was 6.1%. In the general population, however, the prevalence of spina bifida is much less, about 0.1%. Filly [9] studied the predictive ability of the lemon sign in the general population. He assumed that the sensitivity of the lemon sign was 90.0% and the specificity was 98.6% (very similar to that in Nyberg's small study, 92.9% and 98.6%, respectively). In a sample of 10,000 fetuses from a low-risk population (see Table 5), Filly showed that the positive predictive value is only 6%. This is in contrast to the PPV of 81.3% in the Nyberg study. The drastic difference in PPVs is due to the different prevalence rates of spina bifida in the two samples, 6.1% in Nyberg's and 0.1% in Filly's. Thus, while a high-risk fetus with a lemon sign may have an 81% chance of having spina bifida, "a low risk fetus with a lemon sign has a 94% chance of being perfectly normal" [9]. This example illustrates the importance of reporting the pretest probability or prevalence rate of disease whenever one presents a PPV or NPV.
|
Rationale for Ordering a Diagnostic Test
The previous section described how clinicians can use the results of a
diagnostic test to plan a patient's management. Let's back up a bit in the
clinical decision-making process and look at the rationale for ordering a
diagnostic test.
In the simplest scenario (ignoring monetary costs, insurance reimbursement rates, etc.), there are three pieces of information that a clinician needs to determine whether a diagnostic test should or should not be ordered:
In the previous section, we saw how the pretest probability and the test's sensitivity and specificity fit into Bayes' theorem to tell us the posttest probability of disease. We also saw, even for a very accurate test, how the PPV can be quite low when the pretest probability is low. The clinician ordering a test needs to consider how the patient will be managed if the test result is negative versus if the test result is positive. If the probability of disease will still be low after a positive test, then the test may have no impact on the patient's management.
An example is screening for intracranial aneurysms in the general population. The prevalence of aneurysms is low, maybe 1%, in the general population. Even though magnetic resonance angiography (MRA) may have excellent accuracy, say 95% sensitivity and specificity, the PPV is still quite low, 0.16 (16%) from equation 3. Considering the nontrivial risks of invasive catheter angiography (which is the usual presurgical tool) [10], the clinician may decide that even after a positive MRA, the patient should not undergo catheter angiography. In this scenario, the clinician may decide not to order the MRA, given that its result, either positive or negative, will not impact the patient's management.
Designing Studies to Estimate and Compare Tests' Diagnostic Accuracy
As with all new medical devices, treatments, and procedures, the efficacy of diagnostic tests must be assessed in clinical studies. In the second module of this series Jarvik [11] described six levels of diagnostic efficacy. Here, we will focus on the second level, which is the stage at which investigators assess the diagnostic accuracy of a test.
Phases in the Assessment of Diagnostic Test Accuracy
There typically are three phases to the assessment of a diagnostic test's
accuracy [3]. The first is the
exploratory phase. It usually is the first clinical study performed
to assess the efficacy of a new diagnostic test. These tend to be small,
inexpensive studies, typically involving 10 to 50 patients with and without
the disease of interest. The patients selected for the study samples often are
cases with classical overt disease (for example, symptomatic lung cancer) and
healthy volunteer controls. If the test results of these two populations do
not differ, then it is not worth pursuing the diagnostic test further.
The second phase is the challenge phase. Here, we recognize that a diagnostic test's sensitivity and specificity can vary with the extent and stage of the disease, and the comorbidities present. Thus, in this phase we select patients with subtle, or early disease, and with comorbidities that could interfere with the diagnostic test [12]. For example, in a study to assess the ability of MRI to detect lung cancer, the study patients might include those with small nodules (3 cm), and patients with nodules and interstitial disease. The controls might have diseases in the same anatomic location as the disease of interest, for example, interstitial disease but no nodules. These studies often include competing diagnostic tests to compare their accuracies with the test under evaluation. ROC curves are most often used to assess and compare the tests. If the diagnostic test shows good accuracy, then it can be considered for the third phase of assessment.
The third phase is the advanced phase. These studies often are multicenter studies involving large numbers of patients (100 or more). The patient sample should be representative of the target clinical population. For example, instead of selecting patients with known lung cancer and controls without cancer, we might recruit patients presenting to their primary care physician with a persistent cough or bloody sputum. Further testing and follow-up will determine which patients have lung cancer and which do not.
It is from this third phase where we obtain reliable estimates of a test's accuracy for the target clinical population. Estimates of accuracy from the exploratory phase usually are too optimistic because the "sickest of the sick" are compared with the "wellest of the well" [13]. In contrast, estimates of accuracy from the challenge phase often are too low because the patients are exceptionally difficult to diagnose.
Common Features of Diagnostic Test Accuracy Studies
The studies in the three phases differ in terms of their objectives,
sampling of patients, and sample sizes. There are, however, some common
features to all studies of diagnostic test accuracy, as summarized in
Table 6. We elaborate here on a
few important issues.
|
Studies of diagnostic test accuracy require both subjects with and without the disease of interest. If one of these populations is not represented in the study, then either sensitivity or specificity cannot be calculated. We stress that reporting one without reference to the other is uninformative and often misleading. The number of patients needed for diagnostic accuracy studies depends on the phase of the study, the clinical setting in which the test will be applied (for example, screening or diagnostic), and certain characteristics of the patients and test itself (for example, does the test require interpretation by human observers?). Statistical methods are available for determining the appropriate sample size for diagnostic accuracy studies [3, 14].
Studies of diagnostic test accuracy require a test or procedure for determining the true disease status of each patient. This test or procedure is called the "gold standard" (or "standard of reference," "reference standard," particularly when there is no perfect gold standard). The gold, or reference, standard must be conducted and interpreted blinded to the diagnostic test results to avoid bias. Common standards of reference in radiology studies are surgery, pathology results, and clinical follow-up. For example, in the study of Carpenter et al. [2] of the accuracy of MR venography for detecting deep venous thrombosis, contrast venography was used as the reference standard. Sometimes a study uses more than one type of reference standard. For example, in a study to assess the accuracy of mammography, patients with a suspicious lesion on mammography might undergo core biopsy and/or surgery, whereas patients with a negative mammogram would need to be followed for 2 years either to confirm that the patient was cancer free or to detect missed cancers on follow-up screenings. Note that when using different reference standards for patients with positive and negative test results, it is important that all the reference standards are infallible, or nearly so. One form of workup bias occurs when patients with one test result undergo a less rigorous reference standard than patients with a different test result [3].
Determining the appropriate reference standard for a study often is the most difficult part of designing a diagnostic accuracy study. Reference standards should be infallible, or nearly so. This is difficult, however, because even pathology is not infallible, as it is an interpretive field relying on subjective assessment from human observers with varying skill levels. One such example is the reader variability in pathologic interpretation of borderline intraductal breast carcinoma versus atypical ductal carcinoma. While some pathologists may interpret the lesion as intraductal cancer, others may interpret the same lesion as atypical ductal hyperplasia. While often we have to accept that a reference standard is not perfect, it is important that it be nearly infallible. If the reference standard is not nearly infallible, then imperfect gold standard bias can lead to unreliable and misleading estimates of accuracy. Zhou et al. [3] discuss in detail imperfect gold standard bias and possible solutions.
In other situations, no reference standard is available (for example, epilepsy) or it is unethical to subject patients to the reference standard because it poses a risk (for example, an invasive test such as catheter angiography). In these situations, we at least can correlate the test results to other tests' findings and to clinical outcome, even if we cannot report the test's sensitivity and specificity.
It is never an option to omit from the calculation of sensitivity and specificity those patients without a diagnosis confirmed by a reference standard. Such studies yield erroneous estimates of test accuracy due to a form of workup bias called verification bias [17, 18]. This is one of the most common types of bias in radiology studies [19] and is counterintuitive. Investigators often believe they are getting more reliable estimates of accuracy by excluding cases where the reference standard was not performed. If, however, the diagnostic test results were used in the decision of whether to perform the reference standard procedure, then verification bias most likely is present. For example, if the results of MR venography are used to determine which patients will undergo contrast venography, and if patients who did not undergo contrast venography are excluded from the calculations of the test's accuracy, then verification bias exists. Zhou et al. [3] discuss verification bias from a statistical standpoint and offer a variety of solutions.
Summary
We conclude with a summary of five key points in the clinical evaluation of diagnostic tests:
References
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. W. Lee, S. H. Park, K. W. Kim, E. K. Choi, Y. M. Shin, P. N. Kim, K. H. Lee, E. S. Yu, S. Hwang, and S.-G. Lee Unenhanced CT for Assessment of Macrovesicular Hepatic Steatosis in Living Liver Donors: Comparison of Visual Grading with Liver Attenuation Index Radiology, August 1, 2007; 244(2): 479 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gatsonis and P. Paliwal Meta-analysis of diagnostic and screening test accuracy evaluations: methodologic primer. Am. J. Roentgenol., August 1, 2006; 187(2): 271 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Obuchowski ROC Analysis Am. J. Roentgenol., February 1, 2005; 184(2): 364 - 372. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
